A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Exclusion Criteria

• •Pregnancy or breast-feeding
• •Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study
• •Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study
• •Discontinuation of study drug due to a hypersensitivity reaction BCX7353 in a prior study
• •Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology
• •Unacceptable noncompliance in a previous BCX7353 study (if applicable) as assessed by the Sponsor or Investigator
• •Investigational drug exposure, other than BCX7353, within 30 days prior to the screening visit (or baseline if no screening visit)